SCHEMBL11652425

SCHEMBL11652425

COC(=O)C(CC(C(=O)OC)C(=O)OC)C(=O)OC

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
MME P08473 1/20 0.42
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA14 Q9ULX7 2/20 0.39
TSHR P16473 3/20 0.38
ALDH1A1 P00352 1/20 0.37
ZDHHC7 Q9NXF8 1/20 0.37
PTPRB P23467 1/20 0.36
KMT2A Q03164 2/20 0.36
CA12 O43570 1/20 0.36
MGAM O43451 2/20 0.35
GAA P10253 2/20 0.35
SI P14410 2/20 0.35
MGAM2 Q2M2H8 2/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1059738 0.86 MME (0.56) SMN1; SMN2MMECA14ALDH1A1CA12
SCHEMBL28741357 0.86 MME (0.47) SMN1; SMN2MMECA1CA2CA14
SCHEMBL13751258 0.86 SMN1; SMN2 (0.40) SMN1; SMN2MMECA1CA2CA14
SCHEMBL3687345 0.84 SMN1; SMN2 (0.39) SMN1; SMN2MMECA1CA2CA14
SCHEMBL11652987 0.82 TDP1 (0.41) CA1CA2TSHRALDH1A1ZDHHC7
SCHEMBL11652293 0.81 SMN1; SMN2 (0.46) SMN1; SMN2MMECA1CA2CA14
SCHEMBL7164419 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MMECA1CA2CA14
SCHEMBL6696365 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MMECA1CA2CA14
SCHEMBL2097237 0.79 SMN1; SMN2 (0.50) SMN1; SMN2MMECA1CA2CA14
SCHEMBL29120966 0.78 SMN1; SMN2 (0.44) SMN1; SMN2MMECA1CA2CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410276-B2 Method of recycling polyurethane materials CARPENTER ENGINEERED FOAMS BELGIUM BV (BE) 2025-09-09 US disclosed
EP-4010414-B1 IMPROVED METHOD OF RECYCLING POLYURETHANE MATERIALS CARPENTER ENG FOAMS BELGIUM BV (BE) 2025-06-18 EP disclosed
US-20220325031-A1 IMPROVED METHOD OF RECYCLING POLYURETHANE MATERIALS RECTICEL (BE) 2022-10-13 US disclosed
EP-4010414-A1 IMPROVED METHOD OF RECYCLING POLYURETHANE MATERIALS Recticel (BE) 2022-06-15 EP disclosed
CN-114258410-A Improved method for recycling polyurethane materials 雷克蒂塞尔公司 2022-03-29 CN disclosed
US-9676686-B2 Liquid crystal composition containing nitrogen-containing cyclic compound and liquid crystal display device JNC CORPORATION (JP) 2017-06-13 US disclosed
US-9631142-B2 Piperidine derivative, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2017-04-25 US disclosed
US-20160208172-A1 LIQUID CRYSTAL COMPOSITION CONTAINING NITROGEN-CONTAINING CYCLIC COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-07-21 US disclosed
US-20160090534-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-03-31 US disclosed
US-4076601-A FROM DIMETHYL MALONATE MONSANTO COMPANY (US) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160090534-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE MBD2, SSB, MBTD1 SMN1; SMN2 3753/4885MME 4026/4885CA1 725/4885
US-20160208172-A1 LIQUID CRYSTAL COMPOSITION CONTAINING NITROGEN-CONTAINING CYCLIC COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CCND2, ROCK2, CCND1 SMN1; SMN2 3119/4885MME 2663/4885CA1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.